The Role of ICER as an Independent HTA Organisation

Whitepaper

Industry Perceptions and Expectations: The Role of ICER as an Independent HTA Organisation

Hero
 

Who has the job of leading the evaluation of pharmaceutical value and pricing?

 

Over 60% of manufacturers surveyed agreed that the US needs an independent HTA body.

 

The launch of a number of high priced drugs in recent years has led to the perception by some of a fiscally unsustainable US healthcare system. Some stakeholders see a need for a third party, HTA-like organisation in the US, such as ICER (Institute for Clinical and Economic Review), to implement value based frameworks to evaluate the prices of new therapeutics.

 

ICER benchmarks could give payers a means to drive cost savings, resulting in new opportunities and new challenges for manufacturers.

 

Get the insights you need to be prepared. Download our whitepaper for an in depth look at ICON’s primary research to evaluate ICER’s influence over payers and manufactures, as well as a secondary budget impact analysis to estimate the potential savings to the US healthcare system if ICER’s cost effective prices were implemented across a selection of therapeutic areas.

 
READ OUR WHITEPAPER

 

 
     
 
ICONplc.com
 

This email advertisement was sent on behalf of ICON plc by HealthEconomics.Com, 449 S. Mill View Way, Ponte Vedra Beach, FL 32082.
If you don't wish to receive further Industry Leaders News Updates from us, you may immediately unsubscribe from this list here , or send your request in writing to the address above. Read more about our privacy policy here. You may also request a copy in writing using the address above.